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A 67-year-old woman was admitted with signs and symptoms of Graves thyrotoxicosis. Biochemistry results were as follows: TSH
was undetectable; FT4 was >6.99 ng/dL (0.7–1.8); FT3 was 18 pg/mL (3–5); TSI was 658% (0–139).Thyroid uptake and scan showed
diffusely increased tracer uptake in the thyroid gland. The patient was started on methimazole 40mg BID, but her LFTs elevated
precipitously with features of fulminant hepatitis. Methimazole was determined to be the cause and was stopped. After weighing
pros and cons, lithium was initiated to treat her persistent thyrotoxicosis. Lithium 300mg was given daily with a goal to maintain
between 0.4 and 0.6.High doseHydrocortisone and propranolol were also administered concomitantly. Free thyroid hormone levels
decreased and the patient reached a biochemical and clinical euthyroid state in about 8 days. Though definitive RAI was planned,
the patient has been maintained on lithium for more than a month to control her hyperthyroidism. Trial removal of lithium results
in reemergence of thyrotoxicosis within 24 hours. Patient was maintained on low dose lithium treatment with lithium level just
below therapeutic range which was sufficient to maintain euthyroid state for more than a month. There were no signs of lithium
toxicity within this time period. Conclusion. Lithium has a unique physiologic profile and can be used to treat thyrotoxicosis when
thionamides cannot be used while awaiting elective radioablation. Lithium levels need to be monitored; however, levels even at
subtherapeutic range may be sufficient to treat thyrotoxicosis.
1. Introduction
Lithium is an alkali metal used to treat bipolar disorder,
which has been shown to have significant effects on thyroid
function. Lithium carbonate has been used since 1948 to treat
manic-depressive states [1], but it was not until the late 1960s
and early 1970s that hypothyroidism and goiter were noted
as side effects of long-term use of this medication [2, 3]. The
rate of hypothyroidism varies from 0 to 47% [4], likely due
to differences in definitions, study designs, and duration of
lithium treatment. Lithium has been shown to significantly
increase TSH as well as TRH-stimulated release of TSH [5].
This leads to hyperplasia of the thyroid gland and a nontender
goiter formation.We describe a case of Graves’ thyrotoxicosis
that was difficult to control due to antithyroidal drug toxicity.
In this case, the patient’s hyperthyroid state was effectively
controlled with lithium for almost two months.
2. Case Report
A 67-year-old female presented with seizures and fever
to a different institution. The patient had an extensive
medical history, including atypical hemolytic uremic syn-
drome, seizures, diabetes, and hypertension. Graves’ disease
was diagnosed during a prior hospitalization approximately
1.5 months earlier. Her TSH was undetectable, and TSI level
was 658% (0–139%). Thyroid uptake and scan showed a
moderately enlarged gland with diffusely increased tracer
uptake at 43% at 24 hours (normal 8–32%). Methimazole
and propranolol were started, at the other institution, but the
patient developed fulminant hepatitis, which, after extensive
workup, was determined to be due to the methimazole.
Methimazole was withdrawn when the patient presented to
our hospital. She was admitted with history of seizures. She
was not tachycardic or hypertensive. She had a temperature
of 103.9∘F. The Burch-Wartofsky score was 35 [6] and the
Glasgow Coma Scale score was 6. She was in normal sinus
rhythm and showed no signs or symptoms of heart failure.
However, TSH continued to be <0.015mU/L (0.4–4.7), with
elevated FT4 > 6.99 ng/L (0.7–1.8) and FT3 of 18 pg/mL [7–
9]. She was started on 300mg lithium daily which resulted
in a serum level of 0.2mmol/L (therapeutic 0.6–1.2mmol/L).
Other initial labs showed leukocytosis, mild anemia with
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Figure 1: Correlation of free thyroid hormone levels and lithium levels over admission period. (a) shows the levels of free T4, followed by the
levels of free T3 in (b), and corresponding lithium levels over the period of admission on (c). Note the low lithium level required to maintain
euthyroid status over the entire course of hospital admission with no side effects.
occasional schistocytes, as well as a mild rise in AST and
ALT (transaminitis), indirect bilirubinemia, and elevated
lactate dehydrogenase level. The patient was being worked
up for recurrent atypical hemolytic anemia and was deemed
to be unsuitable to undergo thyroidectomy or to receive
radioactive iodine ablation.
After a prolonged debate regarding choice of antithyroid
medication we decided to initiate treatment with lithium.We
initiated intravenous lithium therapy at 150mg TID, and the
dose was titrated to achieve serum lithium levels in the range
of 0.4–0.6mmol/L.
Over the next 5 days TSH rose to 0.3, FT3 normalized, and
FT4 decreased to 1.9 ng/L (Figure 1).We kept following active
hormone levels, that is, FT3 and FT4, closely. The patient’s
mental status improved and she became verbal and coherent
and was able to be transferred out of the intensive care
unit. High dose glucocorticoids and propranolol, which were
started initially, were weaned off and the patient gradually
achieved biochemical and clinical euthyroid status. Free hor-
mone levels completely normalized after 8 days of treatment
at which time lithium level was 0.3mmol/L (Figure 1). The
lithium dose was stabilized at 300mg total daily (split into
twice daily dosing), to maintain levels between 0.4 and
0.6mmol/L. The free hormone levels remained normal until
13 days after initial normalization of free hormone level with
the lithium levels remaining between 0.4 and 0.6mmol/L
(Figure 1).
At this stage, the patient was moved out of the intensive
care unit but remained admitted for observation.
On the 17th day, the patient experienced seizures (11
days after biochemical and clinical stabilization) and required
readmission to intensive care unit with intubation. MRI scan
showed features of acute cerebrovascular accident affecting
the PCA and ACA territories. Patient remained clinically
euthyroid.
We noted increase in FT4 and FT3 levels and at this stage
the lithium levels were at 0.3mmol/L (Figure 1). Lithium
dosing was increased to 300mg in the morning and 150mg
in the evening. On the new higher dose of lithium, the
patient achieved biochemical euthyroid status within 4 days,
and mental status improved. Patient remained biochemically
euthyroid, with lithium level at 0.5–0.6mmol/L (until 27 days
after initial normalization).
On day 28 of admission, lithium was inadvertently
stopped in the intensive care unit and patient did not receive
lithium for the next 72 hours. Lithium levels reached unde-
tectable levels in plasma and free hormone levels immediately
rose again within 24 hours. Lithium was resumed at previous
dosing (300mg in the morning and 150mg in the evening),
with prompt improvement in biochemical thyrotoxicosis.
Over the next few weeks, the patient remained in euthy-
roid state. The patient was sent to a rehabilitation facility to
recover appropriately. While at the center the patient was
maintained on twice daily lithium. Her TSH and free T4
remained satisfactory even on a small dose of lithium (at sub-
therapeutic serum level of lithium) without any fluctuations
of her electrolytes and liver enzymes.
3. Discussion
We have described a patient with thyrotoxicosis who
developed liver toxicity on thionamide therapy and was
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subsequently successfully treated with a prolonged low dose
of lithium, without any side effects.
Hepatotoxicity due to methimazole tends to be more
of a cholestatic process, rather than hepatocellular injury
and allergic hepatitis seen with propylthiouracil toxicity
[7]. Once hepatotoxicity is established, the medication must
be stopped urgently. Generally, an alternative thionamide
is not recommended due to the reported cross-reactivity
between formulations, which is noted to be as high as
50% [10]. In cases of resistant hyperthyroidism, definitive
treatment with radioactive iodine or total thyroidectomy is
considered as soon as possible [11]. Plasmapheresis use has
been documented in limited case reports of life-threatening,
resistant thyrotoxicosis since the 1970s; however there are no
randomized trials or guidelines for its use [12].
Other agents such as beta blockers, steroids, iodine,
cholestyramine, and lithium have traditionally been used as
a temporizing bridge to definitive therapy.
On initial presentation at our center, in our patient,
adequate dose of propranolol was used (40mg three times
daily) titrated to heart rate along with 4mg dexamethasone.
Iodine therapy was considered and indeed the initial use
of lithium by the outside institution showed hyperthyroid
efficacy. However patient on initial presentation was very
unstable and we decided to use lithium so as not to prevent
the radioiodine option and also the patient had a diagnos-
tic whole body CT scan with contrast few days prior to
her admission, which could make further iodine loading
redundant. Moreover, our long-term management plan was
to utilize the radioiodine concentration ability of lithium to
achieve a permanent cure of Graves’ disease.
In that scenario lithium appears to be a good alternative.
It is highly concentrated in the thyroid follicular cells. It has
been shown to inhibit iodine uptake, interfere with tyrosine
iodination, change the thyroglobulin structure, and interfere
with iodotyrosine synthesis [13]. Lithium is also known to
interfere with the sodium-iodide symporter and block iodine
uptake into the follicular cell, reducing the substrate needed
to create thyroid hormone. Lithium blocks thyroid hormone
release from thyroglobulin, which in turn inhibits adenylate
cyclase and prevents thyroid stimulating hormone or thyroid
stimulating antibody from stimulating the cell via the thyroid
hormone receptor [14]. Lastly, lithium inhibits deiodinases in
the periphery.
Lithium has been shown to increase the retention of
radioactive iodine (RAI) in the thyroid of patients with
Graves’ thyrotoxicosis [15], in turn, leading to improvement
of the efficacy of this therapy. Lithium given before or
concomitantly with RAI has been shown to provide more
immediate control of hyperthyroidism, by decreasing the
release of preformed thyroid hormone, without decreasing
the uptake of the RAI [16]. This effect is reminiscent of the
Wolff-Chaikoff effect, where increased iodine content inside
the follicular cell blocks release of hormone. This effect,
much like the effect of iodine, is transient. Older literature
notes the similarity of lithium to iodine and recommends
its use only for short-term, rapid suppression [17]. However,
our case highlights the fact that lithium has several other
mechanisms of action that contribute to long-term control of
thyrotoxicosis.
There are few cases in the literature that describe use of
lithium as a stand-alone drug to treat thyrotoxicosis, without
plan for definitive treatment. In one such study, lithium was
the only drug used to treat 11 patients with Graves’ disease
who relapsed after treatment with conventional antithyroid
medications, radioiodine treatment, or surgery [18]. Patients
were given lithium for 6 months at a dose ranging from 800
to 1200mg daily, with levels in the blood ranging from 0.5
to 1.5mmol/L. Eight of the patients studied became clinically
euthyroid 2 weeks after starting lithium, with thyroid hor-
mone levels decreasing by a mean of 35%. Another 3 patients
took 4–6 weeks to achieve euthyroid state. The important
finding was that euthyroid state was maintained after 6
months, and seven patients relapsed into thyrotoxicosis after
lithium was stopped for 1–4 weeks.
Lithium reaches peak plasma concentration in 1-2 hours
for the immediate release formulation and 4-5 hours for
sustained release formulation. A steady state in the body is
usually achieved after 4 days [14]. Apart from the effects on
the thyroid, reported adverse effects include a spectrum of
central nervous system, cardiovascular, and renal side effects.
These include confusion, coma, seizures, ventricular irritabil-
ity, sinus node dysfunction, sinoatrial block, nephrogenic
diabetes insipidus, electrolyte imbalance, hypercalcemia, and
hypermagnesemia. Studies have shown that lithium doses
of 600mg−1000mg daily (300mg every 8 hours), as well as
lithium blood levels of 0.6–1.2mmol/L, are best to control
thyrotoxicosis. To avoid toxicity, it is best if serum lithium
levels are maintained < 1.0mmol/L, around 0.5mmol/L. [14].
Our case illustrates that a low therapeutic level of lithium
even around 0.2mmol/L is sufficient to suppress thyroid
overactivity without causing side effects. Lithium at a low
dose appears to be an effective antithyroid medication even
for a few months.
4. Conclusion
Lithium can be used to treat thyrotoxicosis when other
more commonly used therapeutic options are not available,
and therapy duration beyond a few weeks is a possibility.
Moreover, as shown in this case, lithium doses in the low,
subtherapeutic range can still be effective in controlling
thyrotoxicosis even over several weeks.
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